EMA Authorised: Praluent (alirocumab) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency has authorised Praluent (alirocumab) for dyslipidaemias, with Sanofi Winthrop Industrie as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidaemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Status: Authorised. Therapeutic area: Dyslipidemias. MAH: Sanofi Winthrop Industrie. Decision date: 17/10/2025